Diaceutics (GB:DXRX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Diaceutics PLC reported a robust first half of 2024 with a 24% revenue growth and a record order book of £27.9m, signaling strong full-year revenue visibility. The company’s recurring revenue reached 55%, aiming for 70% by 2025, alongside a successful launch of PMx and a strategic move towards profitability and enhanced cash flow generation starting from 2025. With a debt-free status and a cash reserve of £16.7 million, Diaceutics is poised for continued success in the precision medicine market.
For further insights into GB:DXRX stock, check out TipRanks’ Stock Analysis page.
